Voyager Therapeutics, Inc. (VYGR) Stock

Voyager Therapeutics, Inc. (VYGR) is a Healthcare stock trading at $3.71 (as of 2026-06-18), with a market capitalization of $217.82M and a trailing P/E of -1.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Voyager Therapeutics develops gene-therapy treatments and related platform technologies, including its lead program VY-AADC in an open-label Phase 1 trial for Parkinson’s disease. Its preclinical pipeline includes AADC, SOD102 for amyotrophic lateral sclerosis, HTT01 for Huntington’s disease, FXN01 for Friedreich’s ataxia, and additional tau and spinal muscular atrophy programs, with collaboration and licensing agreements involving Neurocrine Biosciences, Pfizer, and Novartis.

Valuation — source: SEC EDGAR (first-party)
Price	$3.71
Market Cap	$217.82M
P/E Ratio	-1.8
EV / EBITDA	-1.4
Price / Book	1.25
Price / Sales	5.97
DCF Value (model)	$-37.44
DCF Upside vs Price	-1109.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$40.37M
Net Margin	-296.5%
Return on Equity	-67.2%
Current Ratio	8.42
Revenue Growth (YoY)	-49.5%
EPS Growth (YoY)	80.5%
FCF Growth (YoY)	617.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.84 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-108.7%
vs Industry	-110.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($21.49M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Alfred W. Sandrock Jr.
Employees	172
Country	US
IPO Date	2015-11-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.